Previous 10 | Next 10 |
60-patient enrollment target met plus 12% over-enrollment; top-line Phase 2a results expected to be presented during the European Sleep Research Society Congress in September 2022 Nearly 90% of patients completing the Phase 2a trial to date have rolled over into the open label extensio...
The shares of NLS Pharmaceutics (NASDAQ:NLSP) spiked in the pre-market Wednesday after the Swiss pharmaceutical company announced that its Phase 2a clinical trial for Quilience narcolepsy achieved 90% of enrollment. Out of the 60 patients targeted, the company has so far enrolled 54 patients,...
Since the interim results were released in March, patient enrollment has nearly doubled Of the 60 patients planned for the study, 54 have now been randomized with several others currently undergoing screening Nearly 90% of patients that completed the Phase 2a trial to date have ro...
ZURICH, SWITZERLAND / ACCESSWIRE / April 26, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central n...
ZURICH, SWITZERLAND / ACCESSWIRE / April 22, 2022 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous sys...
NLS Pharmaceutics (NASDAQ:NLSP) has announced a $4.4M share offering priced at-the-market under Nasdaq rules. The Swiss biopharmaceutical company entered into definitive agreements with health-care focused institutional investors, alongside its Board Chairman Ronald Hafner, for the purchase a...
ZURICH, SWITZERLAND / ACCESSWIRE / April 13, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central ne...
ZURICH, SWITZERLAND / ACCESSWIRE / April1, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nerv...
ZURICH, SWITZERLAND / ACCESSWIRE / March 31, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) (NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central ne...
Named Patient Program (NPP) enables physicians to prescribe the Company's novel Mazindol Extended-Release (ER) formulation to patients who have failed approved therapies Product sales through the NPP are expected to be revenue-generating, with patient access anticipated to begin in Q2 ...
News, Short Squeeze, Breakout and More Instantly...
NLS Pharmaceutics Ltd. Company Name:
NLSP Stock Symbol:
NASDAQ Market:
NLS Pharmaceutics Ltd. Website:
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.3% to $111.59 on volume of 240,827,673 shares Lipella Pharmaceuticals Inc. (LIPO) rose 122.5% to $0.8992 on volume of 193,926,302 shares PROSHARES TRUST (SQQQ) fell 0.5% to $9.05 on volume of 150,372,371...
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy platform Each of Kadimastem and NLS Pharmaceutics has received commitments of support f...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...